Surface Logix Raises $20 Million in Financing and Starts Phase 2b Clinical Trial of SLx-4090 in Dyslipidemia and Diabetes
3/9/2009 8:14:29 AM
More...
|
Surface Logix Appoints Keith Dionne as President and Chief Executive Officer
10/14/2008 6:24:07 AM
More...
|
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
1/29/2008 7:08:26 AM
More...
|
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
1/8/2008 8:01:53 AM
More...
|
Surface Logix SLx-4090 Selected Among Top 10 Most Promising Licensing Candidates In Cardiovascular Disease
10/18/2007 7:50:15 AM
More...
|
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090
10/5/2007 8:20:00 AM
More...
|
Surface Logix to Present at the 2007 Biotechnology Industry Organization (BIO) Investor Forum
10/3/2007 7:50:20 AM
More...
|
Surface Logix Announces the Appointment of Leland Webster as Vice President of Corporate Development
8/21/2007 8:28:51 AM
More...
|
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease
6/28/2007 10:37:53 AM
More...
|
Surface Logix Commences Phase 2A Clinical Trial of SLx-2101 in Hypertension
6/19/2007 10:09:38 AM
More...
|
|